FDA panel endorses efficacy but not safety of Novartis drug ACZ885 for gouty arthritis
- Details
- Category: Novartis
An advisory committee of the Food and Drug Administration (FDA) today voted in favor of the overall efficacy but not the overall safety of ACZ885 (canakinumab) to treat gouty arthritis attacks in patients who cannot obtain adequate relief with non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine.
Pivotal study showed vismodegib helped shrink tumours or heal lesions
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform
- Details
- Category: Genzyme
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced the launch of a new web-based platform, RegistryNXT!SM, to support the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia
- Details
- Category: Novartis
Novartis held a groundbreaking ceremony to announce the start of construction of a pharmaceutical manufacturing plant in St. Petersburg, Russia. The construction of this facility represents the most significant Novartis investment in Russia to date.
AstraZeneca extends its investment in Russia
- Details
- Category: AstraZeneca
AstraZeneca announced today that it plans to establish a Predictive Science Centre in St. Petersburg over the coming year. The move strengthens AstraZeneca's investments in Russia and supports the Russian Government's strategy to modernise and develop the country's pharmaceutical sector.
Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets
- Details
- Category: Nycomed
Nycomed has completed the transfer of marketing authorisation approvals in a number of key Asia-Pacific markets for osteoporosis treatment Bonviva (Ibandronate). The licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) marks a further strengthening of Nycomed's bone health franchise in the region.
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has entered into an agreement to acquire the remaining 51% equity interest of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd (Neptunus) in the joint venture (JV) company, Shenzhen GSK-Neptunus Biologicals Co. Ltd. (GSKNB), for a total cash consideration of£24 million (US$39 million).
More Pharma News ...
- Synthes and Lilly Sign Development and Collaboration Agreement
- GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
- Abbott Reports Interim Results From Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease
- Millions of children in the world's poorest countries could receive vaccination against rotavirus diarrhoeal disease
- Pfizer Conducts First "Virtual" Clinical Trial Allowing Patients to Participate Regardless of Geography
- Novartis drug Glivec® shows significant overall survival benefit
- Pfizer and Hisun Sign MOU to Establish a Joint Venture